Abstract

PRE-CLINICAL STUDIES OF THE ANTI-TUBULATIVE DRUG “BIOMAIRIN”

*Mamatmusaeva N. E., Shomuratov Sh. A., Sagdullaev B. T. and Turaev A. S.

ABSTRACT

By chemical modification of polygalacturonic acid with anti-TB drugs with isoniazid, ethambutol and rifampicin, the macromolecular system Biomairin was obtained. Pharmaco-toxicological studies have established that Biomairin is less toxic than low-molecular analogs and has a pronounced anti-tuberculosis activity, and at a two-fold lower dose when calculated on the active substance, it has identical activity with the combined anti-tuberculosis drug Mairin. Pharmacokinetic studies have shown that with the introduction of Biomairin, the therapeutic concentration of the active ingredients (isoniazid, ethambutol and rifampicin) in the blood lasts longer than their low-molecular counterparts. It should also be noted that the chemical binding of isoniazid to the polysaccharide matrix slows down its metabolism to therapeutically inactive acetylisoniazid.

Keywords: polygalacturonic acid, isoniazid, ethambutol, rifampicin, mayrin, carrier polymer, tuberculosis, prolongation.